http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105884868-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-08 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K101-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 |
| filingDate | 2016-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105884868-B |
| titleOfInvention | It is a kind of18The affinity body class compound and the preparation method and application thereof of F label |
| abstract | The invention belongs to radiopharmaceutical and the field of nuclear medicines, and in particular to a kind of 18 The affinity body class compound and the preparation method and application thereof of F label.It is of the present invention 18 The affinity body class compound of F label, on the one hand, tumour is higher to its uptake values, and tumor imaging sensitivity is higher, and on the other hand, liver is lower to its uptake values, smaller to the toxic side effect of liver；Animal experiments show that described 18 The affinity body class compound of F label, residence time, higher target/non-target ratio and the preferable pharmacokinetic property that tumour is higher to its uptake values, shorter, biological property is excellent, can be used as the PET tumor imaging agent for targeting HER2 receptor；Not only cost is relatively low for preparation method, simple and convenient for operation, but also mark rate is higher, the radiochemical purity of marked product is higher, is conducive to be prepared 18 The affinity body class compound of F label is clinically promoted and applied as the PET tumor imaging agent for targeting HER2 receptor. |
| priorityDate | 2016-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.